JP2004531468A5 - - Google Patents

Download PDF

Info

Publication number: JP2004531468A5
Authority: JP; Japan
Prior art keywords: pain; composition; uridine; muscle; salt
Prior art date: 2001-11-29
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

JP2002545692A

Other languages

English (en)

Japanese (ja)

Other versions

JP4596734B2 (ja

JP2004531468A (ja

Filing date

2001-11-29

Publication date

2009-04-02

2000-11-29 Priority claimed from AUPR1773A external-priority patent/AUPR177300A0/en

2001-11-29 Application filed filed Critical

2004-10-14 Publication of JP2004531468A publication Critical patent/JP2004531468A/ja

2009-04-02 Publication of JP2004531468A5 publication Critical patent/JP2004531468A5/ja

2010-12-15 Application granted granted Critical

2010-12-15 Publication of JP4596734B2 publication Critical patent/JP4596734B2/ja

2021-11-29 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 claims description 44
ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims description 22
DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 claims description 22
235000017471 coenzyme Q10 Nutrition 0.000 claims description 22
DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 claims description 22
229940045145 uridine Drugs 0.000 claims description 22
229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 20
208000000112 Myalgia Diseases 0.000 claims description 20
208000013465 muscle pain Diseases 0.000 claims description 19
230000000694 effects Effects 0.000 claims description 17
239000000203 mixture Substances 0.000 claims description 15
238000011282 treatment Methods 0.000 claims description 14
150000003839 salts Chemical class 0.000 claims description 11
239000002243 precursor Substances 0.000 claims description 10
239000003814 drug Substances 0.000 claims description 9
QWLHYYKDLOVBNV-UHFFFAOYSA-L magnesium orotate Chemical group [Mg+2].[O-]C(=O)C1=CC(=O)NC(=O)N1.[O-]C(=O)C1=CC(=O)NC(=O)N1 QWLHYYKDLOVBNV-UHFFFAOYSA-L 0.000 claims description 9
ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 8
229940110767 coenzyme Q10 Drugs 0.000 claims description 8
PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 claims description 8
238000002560 therapeutic procedure Methods 0.000 claims description 8
150000002148 esters Chemical class 0.000 claims description 7
229960000407 magnesium orotate Drugs 0.000 claims description 7
206010039020 Rhabdomyolysis Diseases 0.000 claims description 6
208000008035 Back Pain Diseases 0.000 claims description 5
206010011224 Cough Diseases 0.000 claims description 5
206010019233 Headaches Diseases 0.000 claims description 5
208000007101 Muscle Cramp Diseases 0.000 claims description 5
206010037660 Pyrexia Diseases 0.000 claims description 5
210000003489 abdominal muscle Anatomy 0.000 claims description 5
208000002173 dizziness Diseases 0.000 claims description 5
231100000869 headache Toxicity 0.000 claims description 5
206010039083 rhinitis Diseases 0.000 claims description 5
201000009890 sinusitis Diseases 0.000 claims description 5
208000019116 sleep disease Diseases 0.000 claims description 5
208000006820 Arthralgia Diseases 0.000 claims description 4
229960005010 orotic acid Drugs 0.000 claims description 4
230000011514 reflex Effects 0.000 claims description 4
238000001727 in vivo Methods 0.000 claims description 3
230000000638 stimulation Effects 0.000 claims description 3
XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims description 2
XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims description 2
PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims description 2
TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 claims description 2
RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims description 2
230000002411 adverse Effects 0.000 claims description 2
229960005370 atorvastatin Drugs 0.000 claims description 2
229960005110 cerivastatin Drugs 0.000 claims description 2
SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 claims description 2
229960004844 lovastatin Drugs 0.000 claims description 2
PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims description 2
QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims description 2
229960002965 pravastatin Drugs 0.000 claims description 2
TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims description 2
229960002855 simvastatin Drugs 0.000 claims description 2
RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims description 2
ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 claims 1
229960003765 fluvastatin Drugs 0.000 claims 1
238000004519 manufacturing process Methods 0.000 claims 1
239000000546 pharmaceutical excipient Substances 0.000 claims 1
208000002193 Pain Diseases 0.000 description 31
206010016256 fatigue Diseases 0.000 description 18
150000001875 compounds Chemical class 0.000 description 16
229940079593 drug Drugs 0.000 description 8
239000003826 tablet Substances 0.000 description 7
239000007788 liquid Substances 0.000 description 6
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
208000035150 Hypercholesterolemia Diseases 0.000 description 4
239000004480 active ingredient Substances 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
239000008280 blood Substances 0.000 description 4
239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 4
238000000034 method Methods 0.000 description 4
208000024891 symptom Diseases 0.000 description 4
206010067125 Liver injury Diseases 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
239000002775 capsule Substances 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
239000008187 granular material Substances 0.000 description 3
231100000753 hepatic injury Toxicity 0.000 description 3
238000000465 moulding Methods 0.000 description 3
239000000843 powder Substances 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
108010082126 Alanine transaminase Proteins 0.000 description 2
208000035473 Communicable disease Diseases 0.000 description 2
102000004420 Creatine Kinase Human genes 0.000 description 2
108010042126 Creatine kinase Proteins 0.000 description 2
241000701022 Cytomegalovirus Species 0.000 description 2
HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 2
108010023302 HDL Cholesterol Proteins 0.000 description 2
241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
208000031226 Hyperlipidaemia Diseases 0.000 description 2
238000008214 LDL Cholesterol Methods 0.000 description 2
108010028554 LDL Cholesterol Proteins 0.000 description 2
206010049565 Muscle fatigue Diseases 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
229940035676 analgesics Drugs 0.000 description 2
239000000730 antalgic agent Substances 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
229960003627 gemfibrozil Drugs 0.000 description 2
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
229960003512 nicotinic acid Drugs 0.000 description 2
235000001968 nicotinic acid Nutrition 0.000 description 2
239000011664 nicotinic acid Substances 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
238000013077 scoring method Methods 0.000 description 2
229940126585 therapeutic drug Drugs 0.000 description 2
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
238000010200 validation analysis Methods 0.000 description 2
HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
DKSZLDSPXIWGFO-BLOJGBSASA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;phosphoric acid;hydrate Chemical compound O.OP(O)(O)=O.OP(O)(O)=O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC DKSZLDSPXIWGFO-BLOJGBSASA-N 0.000 description 1
JSEYDHRHJGYMLT-PNHWDRBUSA-N 1-[(2s,3r,4s,5r)-2-acetyl-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione Chemical compound C1=CC(=O)NC(=O)N1[C@]1(C(=O)C)O[C@H](CO)[C@@H](O)[C@H]1O JSEYDHRHJGYMLT-PNHWDRBUSA-N 0.000 description 1
FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
206010005003 Bladder cancer Diseases 0.000 description 1
108010006654 Bleomycin Proteins 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
229920001268 Cholestyramine Polymers 0.000 description 1
206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
KPSRODZRAIWAKH-JTQLQIEISA-N Ciprofibrate Natural products C1=CC(OC(C)(C)C(O)=O)=CC=C1[C@H]1C(Cl)(Cl)C1 KPSRODZRAIWAKH-JTQLQIEISA-N 0.000 description 1
229920002911 Colestipol Polymers 0.000 description 1
206010009944 Colon cancer Diseases 0.000 description 1
MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
229920002785 Croscarmellose sodium Polymers 0.000 description 1
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
229930105110 Cyclosporin A Natural products 0.000 description 1
108010036949 Cyclosporine Proteins 0.000 description 1
108010092160 Dactinomycin Proteins 0.000 description 1
206010012289 Dementia Diseases 0.000 description 1
208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
102000009123 Fibrin Human genes 0.000 description 1
108010073385 Fibrin Proteins 0.000 description 1
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
108010069236 Goserelin Proteins 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
208000008839 Kidney Neoplasms Diseases 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
206010028289 Muscle atrophy Diseases 0.000 description 1
208000029549 Muscle injury Diseases 0.000 description 1
241001553014 Myrsine salicina Species 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
206010060862 Prostate cancer Diseases 0.000 description 1
208000000236 Prostatic Neoplasms Diseases 0.000 description 1
206010038389 Renal cancer Diseases 0.000 description 1
208000000453 Skin Neoplasms Diseases 0.000 description 1
PGAVKCOVUIYSFO-XVFCMESISA-N UTP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 PGAVKCOVUIYSFO-XVFCMESISA-N 0.000 description 1
DJJCXFVJDGTHFX-UHFFFAOYSA-N Uridinemonophosphate Natural products OC1C(O)C(COP(O)(O)=O)OC1N1C(=O)NC(=O)C=C1 DJJCXFVJDGTHFX-UHFFFAOYSA-N 0.000 description 1
208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
208000002495 Uterine Neoplasms Diseases 0.000 description 1
241000700605 Viruses Species 0.000 description 1
RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
229940009456 adriamycin Drugs 0.000 description 1
229940124599 anti-inflammatory drug Drugs 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
229960002537 betamethasone Drugs 0.000 description 1
UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
229960000516 bezafibrate Drugs 0.000 description 1
IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 description 1
239000003613 bile acid Substances 0.000 description 1
229960001561 bleomycin Drugs 0.000 description 1
OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
235000021152 breakfast Nutrition 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
229960004562 carboplatin Drugs 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
229940044683 chemotherapy drug Drugs 0.000 description 1
229960001265 ciclosporin Drugs 0.000 description 1
229960002174 ciprofibrate Drugs 0.000 description 1
KPSRODZRAIWAKH-UHFFFAOYSA-N ciprofibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1C1C(Cl)(Cl)C1 KPSRODZRAIWAKH-UHFFFAOYSA-N 0.000 description 1
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
229960004316 cisplatin Drugs 0.000 description 1
238000011260 co-administration Methods 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
229960004415 codeine phosphate Drugs 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
208000029742 colonic neoplasm Diseases 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
238000011284 combination treatment Methods 0.000 description 1
239000007891 compressed tablet Substances 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
239000003246 corticosteroid Substances 0.000 description 1
229960001334 corticosteroids Drugs 0.000 description 1
229960004544 cortisone Drugs 0.000 description 1
239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
229930182912 cyclosporin Natural products 0.000 description 1
229960000640 dactinomycin Drugs 0.000 description 1
STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
229960000975 daunorubicin Drugs 0.000 description 1
229960003957 dexamethasone Drugs 0.000 description 1
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
201000010099 disease Diseases 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
229960004679 doxorubicin Drugs 0.000 description 1
229960001904 epirubicin Drugs 0.000 description 1
229960005420 etoposide Drugs 0.000 description 1
VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
229960002297 fenofibrate Drugs 0.000 description 1
YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 1
229950003499 fibrin Drugs 0.000 description 1
229960000390 fludarabine Drugs 0.000 description 1
GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
229960002913 goserelin Drugs 0.000 description 1
208000005252 hepatitis A Diseases 0.000 description 1
229960000890 hydrocortisone Drugs 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
230000007794 irritation Effects 0.000 description 1
201000010982 kidney cancer Diseases 0.000 description 1
238000011866 long-term treatment Methods 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
201000005202 lung cancer Diseases 0.000 description 1
208000020816 lung neoplasm Diseases 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
229940091250 magnesium supplement Drugs 0.000 description 1
238000005259 measurement Methods 0.000 description 1
235000013372 meat Nutrition 0.000 description 1
229960004584 methylprednisolone Drugs 0.000 description 1
229960001156 mitoxantrone Drugs 0.000 description 1
KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
239000007932 molded tablet Substances 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
201000000585 muscular atrophy Diseases 0.000 description 1
208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
229960005489 paracetamol Drugs 0.000 description 1
229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
229960005205 prednisolone Drugs 0.000 description 1
OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 1
229960003912 probucol Drugs 0.000 description 1
210000002307 prostate Anatomy 0.000 description 1
238000007493 shaping process Methods 0.000 description 1
210000002027 skeletal muscle Anatomy 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
201000000849 skin cancer Diseases 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000008109 sodium starch glycolate Substances 0.000 description 1
229940079832 sodium starch glycolate Drugs 0.000 description 1
229920003109 sodium starch glycolate Polymers 0.000 description 1
239000007787 solid Substances 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
229960001603 tamoxifen Drugs 0.000 description 1
238000012360 testing method Methods 0.000 description 1
DJJCXFVJDGTHFX-XVFCMESISA-N uridine 5'-monophosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 DJJCXFVJDGTHFX-XVFCMESISA-N 0.000 description 1
229950010342 uridine triphosphate Drugs 0.000 description 1
PGAVKCOVUIYSFO-UHFFFAOYSA-N uridine-triphosphate Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)OC1N1C(=O)NC(=O)C=C1 PGAVKCOVUIYSFO-UHFFFAOYSA-N 0.000 description 1
210000003932 urinary bladder Anatomy 0.000 description 1
201000005112 urinary bladder cancer Diseases 0.000 description 1
206010046766 uterine cancer Diseases 0.000 description 1
210000004291 uterus Anatomy 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

JP2002545692A 2000-11-29 2001-11-29 スタチン副作用の処置 Expired - Fee Related JP4596734B2 (ja)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
AUPR1773A AUPR177300A0 (en)	2000-11-29	2000-11-29	Therapeutic methods
PCT/AU2001/001545 WO2002043721A1 (en)	2000-11-29	2001-11-29	Treatment of statin side effects

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2010151665A Division JP2010248230A (ja)	2000-11-29	2010-07-02	スタチン副作用の処置

Publications (3)

Publication Number	Publication Date
JP2004531468A JP2004531468A (ja)	2004-10-14
JP2004531468A5 true JP2004531468A5 (da)	2009-04-02
JP4596734B2 JP4596734B2 (ja)	2010-12-15

Family

ID=3825810

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
JP2002545692A Expired - Fee Related JP4596734B2 (ja)	2000-11-29	2001-11-29	スタチン副作用の処置
JP2010151665A Pending JP2010248230A (ja)	2000-11-29	2010-07-02	スタチン副作用の処置

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
JP2010151665A Pending JP2010248230A (ja)	2000-11-29	2010-07-02	スタチン副作用の処置

Country Status (10)

Country	Link
US (3)	US20040063661A1 (da)
EP (1)	EP1343488B1 (da)
JP (2)	JP4596734B2 (da)
AT (1)	ATE369845T1 (da)
AU (3)	AUPR177300A0 (da)
CA (1)	CA2429979C (da)
DE (1)	DE60130023T2 (da)
ES (1)	ES2292643T3 (da)
NZ (1)	NZ526069A (da)
WO (1)	WO2002043721A1 (da)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AUPR951101A0 (en)	2001-12-13	2002-01-24	Centre For Molecular Biology And Medicine	Method of treatment
EP1641444B1 (en) *	2003-06-02	2016-03-23	Isis Innovation Limited	Treatment of muscle fatigue
AU2004245567B2 (en)	2003-06-03	2011-06-23	Oxford University Innovation Limited	Nutritional supplements and therapeutic compositions comprising (R)-3-hydroxybutyrate derivatives
KR101395370B1 (ko)	2004-01-22	2014-05-14	유니버시티 오브 마이애미	국소용 코-엔자임 큐10 제형 및 그의 사용 방법
RU2007102086A (ru) *	2004-06-21	2008-07-27	Хатчисон Медифарма Энтерпрайзис Лимитед (Bs)	Химиотерапия рака
WO2006009840A1 (en) *	2004-06-21	2006-01-26	Hutchison Medipharma Enterprises Limited	Benzoquinone compounds as a anti-cancer agents
JP4896501B2 (ja) *	2004-11-26	2012-03-14	第一三共株式会社	血中遊離脂肪酸低下作用を有する医薬組成物
WO2006057209A1 (ja) *	2004-11-26	2006-06-01	Sankyo Company, Limited	血中遊離脂肪酸低下作用を有する医薬組成物
US20060252831A1 (en) *	2005-05-06	2006-11-09	Christopher Offen	Method for the treatment of magnesium and potassium deficiencies
US20060252830A1 (en) *	2005-05-06	2006-11-09	Brandon Stephen F	Method for the treatment of magnesium and potassium deficiencies
CA2996149A1 (en)	2005-06-01	2006-12-07	Bioelectron Technology Corporation	Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
AU2006338839A1 (en) *	2006-02-23	2007-08-30	Iomedix Sleep International Srl	Compositions and methods for the induction and maintenance of quality sleep
WO2007127908A2 (en) *	2006-04-28	2007-11-08	Hutchison Medipharma Enterprises Limited	Dihydrobenzoquinone compounds
MX2008013855A (es) *	2006-05-02	2009-01-29	Univ Miami	Formulaciones de co-enzima topica q10 y tratamiento de dolor, fatiga y heridas.
DK2240017T3 (da)	2008-01-04	2019-06-17	Univ Oxford Innovation Ltd	Ketonlegemer og ketonlegemsestere som blodlipid-sænkende midler
CL2009000478A1 (es)	2008-02-29	2009-08-07	Biolab Sanus Farmaceutica Ltda	Composicion farmaceutica que comprende piracetam o una sal del mismo, l-carnitina y un vehiculo; proceso de preparacion de la composicion; y su uso para el tratamiento y/o prevencion de trastornos mitocondriales relacionados con efectos colaterales inducidos por farmacos, tal como enfermedad de alzheimer o mal de parkinson.
WO2009126764A1 (en)	2008-04-11	2009-10-15	Cytotech Labs, Llc	Methods and use of inducing apoptosis in cancer cells
US8642654B2 (en)	2009-04-16	2014-02-04	Isis Innovation Limited	Hydroxybutyrate ester and medical use thereof
CA2736250C (en)	2008-09-10	2016-12-20	Edison Pharmaceuticals, Inc.	Treatment of pervasive developmental disorders with redox-active therapeutics
JP5426918B2 (ja) *	2009-04-20	2014-02-26	株式会社伊藤園	ウリジンを含有する抗疲労剤又は体力向上剤
JP5903735B2 (ja)	2009-05-11	2016-04-13	バーグエルエルシー	エピメタボリックシフター（コエンザイムｑ１０）を使用した疾患の処置方法
US8557236B2 (en) *	2010-02-09	2013-10-15	Vascure Natural LLC	Cardiovascular support supplement and compositions and methods thereof
GB201002983D0 (en)	2010-02-22	2010-04-07	Tdeltas Ltd	Nutritinal composition
WO2012138765A1 (en)	2011-04-04	2012-10-11	Berg Pharma Llc	Methods of treating central nervous system tumors
EP2744492A1 (en) *	2011-08-15	2014-06-25	Technion Research & Development Foundation	Combinations of corroles and statins
TWI489982B (zh) *	2012-09-18	2015-07-01	Univ China Medical	苯醌類化合物應用於抑制動脈粥狀血管硬化之用途
TWI504390B (zh) *	2012-09-18	2015-10-21	Univ China Medical	苯醌類化合物應用於抑制黑色素瘤細胞之Ｗｎｔ／β－ｃａｔｅｎｉｎ訊息途徑之用途
AU2013337308B2 (en)	2012-11-05	2018-06-21	Tdeltas	Ketone bodies to protect tissues from damage by ionizing radiation
GB201304467D0 (en)	2013-03-12	2013-04-24	Tdeltas Ltd	Compound for use in protecting skin
CA2905225C (en)	2013-03-14	2021-05-04	Isis Innovation Limited	Process for producing (r)-3-hydroxybutyl (r)-3-hydroxybutyrate
NZ713868A (en)	2013-04-08	2021-12-24	Berg Llc	Treatment of cancer using coenzyme q10 combination therapies
WO2015003246A1 (en) *	2013-07-09	2015-01-15	Mcmaster University	Combination of a statin with an inflammasome inhibitor
JP6595478B2 (ja)	2013-09-04	2019-10-23	バーグエルエルシー	コエンザイムｑ１０の連続注入によるがんの治療方法
WO2017087576A1 (en)	2015-11-16	2017-05-26	Berg Llc	Methods of treatment of temozolomide-resistant glioma using coenzyme q10
EP3389646A1 (en)	2015-12-17	2018-10-24	BioElectron Technology Corporation	Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders
MA52274A (fr)	2017-05-17	2021-02-24	Berg Llc	Utilisation de formulations de coenzyme q10 dans le traitement et la prévention de l'épidermolyse bulleuse
WO2018218287A1 (en) *	2017-05-29	2018-12-06	Woodlinda Pty Ltd	Treatment and/or prevention of neuropathic symptoms associated with diabetes mellitus type ii
CA3078808A1 (en) *	2017-10-13	2018-10-12	Exerkine Corporation	Use of system xc- inhibitor for treating statin-induced myalgia
KR102060722B1 (ko) *	2017-11-06	2020-02-11	연세대학교 산학협력단	스타틴에 의한 약물유해반응용 동물 모델 및 이의 제조방법

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2462312A1 (de) *	1974-03-04	1976-10-14	Nadrol Chemie Pharma Keizer Kg	Arzneimittel zur behandlung von migraene-erkrankungen
SU988814A1 (ru) *	1979-11-20	1983-01-15	Филиал Всесоюзного научно-исследовательского химико-фармацевтического института им.Серго Орджоникидзе	Соли оротовой кислоты и @ -аминокислот, предупреждающие развитие утомлени при физических нагрузках
DE3110560A1 (de) *	1981-03-18	1982-10-14	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen	"angiotropine der leukozyten und des entzuendungsgewebes: eine neue klasse natuerlicher chemotropischer mitogene fuer das richtungswachstum von blutgefaessen und zur neovaskularisierung von geweben"
US4911917A (en) *	1988-06-28	1990-03-27	Hauser-Kuhrts, Inc.	Cholesterol-lowering combination comopsitions of magnesium salt and niacin
DE69001146T2 (de) *	1989-01-18	1993-10-07	Merck & Co Inc	Koenzym Q10 mit HMG-COA-Reduktase-Inhibitoren.
US4929437A (en) *	1989-02-02	1990-05-29	Merck & Co., Inc.	Coenzyme Q10 with HMG-CoA reductase inhibitors
US5316765A (en) *	1989-09-07	1994-05-31	Karl Folkers Foundation For Biomedical And Clinical Research	Use of coenzyme Q10 in combination with HMG-CoA reductase inhibitor therapies
EP0627921B1 (en) *	1992-02-24	2000-05-31	East Carolina University	Method of inhibiting carcinogenesis by treatment with dehydroepiandrosterone and analogs thereof
BE1005939A6 (fr) *	1992-05-14	1994-03-15	Pirmez Thierry Dr	Utilisation des sels de l'acide orotique comme tranporteurs preferentiels d'oligo-elements.
DE69333575T2 (de) *	1992-05-28	2005-08-25	Centre For Molecular Biology And Medicine, Richmond	Quinone-derivate zur verbesserung der zellulare bioenergie
AT405477B (de) *	1996-04-03	1999-08-25	Norbert Mag Fuchs	Kombinationspräparat
US6472378B2 (en) *	1998-08-31	2002-10-29	Pro-Neuron, Inc.	Compositions and methods for treatment of mitochondrial diseases
US6245800B1 (en) *	1999-06-08	2001-06-12	Sigma-Tau	Method of preventing or treating statin-induced toxic effects using L-carnitine or an alkanoyl L-carnitine
IT1317008B1 (it) *	2000-04-04	2003-05-26	Sigma Tau Healthscience Spa	Integratore alimentare energizzante sulla muscolatura scheletrica eprotettivo sull'apparato cardiovascolare.
US6420342B1 (en) *	2000-05-08	2002-07-16	N.V. Nutricia	Nutritional preparation comprising ribose and medical use thereof

2000
- 2000-11-29 AU AUPR1773A patent/AUPR177300A0/en not_active Abandoned
2001
- 2001-11-29 DE DE60130023T patent/DE60130023T2/de not_active Expired - Lifetime
- 2001-11-29 EP EP01998341A patent/EP1343488B1/en not_active Expired - Lifetime
- 2001-11-29 AT AT01998341T patent/ATE369845T1/de not_active IP Right Cessation
- 2001-11-29 NZ NZ526069A patent/NZ526069A/en not_active IP Right Cessation
- 2001-11-29 AU AU2330202A patent/AU2330202A/xx active Pending
- 2001-11-29 ES ES01998341T patent/ES2292643T3/es not_active Expired - Lifetime
- 2001-11-29 US US10/433,074 patent/US20040063661A1/en not_active Abandoned
- 2001-11-29 CA CA2429979A patent/CA2429979C/en not_active Expired - Fee Related
- 2001-11-29 WO PCT/AU2001/001545 patent/WO2002043721A1/en active IP Right Grant
- 2001-11-29 JP JP2002545692A patent/JP4596734B2/ja not_active Expired - Fee Related
- 2001-11-29 AU AU2002223302A patent/AU2002223302B2/en not_active Ceased
2010
- 2010-02-16 US US12/706,257 patent/US20100144665A1/en not_active Abandoned
- 2010-07-02 JP JP2010151665A patent/JP2010248230A/ja active Pending
- 2010-08-04 US US12/849,943 patent/US20100323981A1/en not_active Abandoned

Publication	Publication Date	Title
JP2004531468A5 (da)	2009-04-02
JP4596734B2 (ja)	2010-12-15	スタチン副作用の処置
JP5690261B2 (ja)	2015-03-25	β−ヒドロキシ−β−メチル酪酸および少なくとも１つのアミノ酸を含む組成物および使用法
RU2404750C2 (ru)	2010-11-27	Композиция, содержащая основу или покрытие для замедленного высвобождения и антагонист nmda рецептора, способ введения такого nmda антагониста субъекту
RU2472511C2 (ru)	2013-01-20	Композиции и способы применения форболовых эфиров
JP2005041875A (ja)	2005-02-17	アトルバスタチンと血圧降下薬とを含む組み合わせ療法
AU2002223302A1 (en)	2002-08-15	Treatment of statin side effects
JPH0635382B2 (ja)	1994-05-11	抗不安薬としてのフルオキセチンの使用法
KR20020086749A (ko)	2002-11-18	베타 블록커 및 콜레스테롤 저하제의 신규한 조합물
JP2009545546A (ja)	2009-12-24	リウマチ性疾患の遅延放出型グルココルチコイド治療
EP0680756B1 (en)	1999-08-18	Use of a combination of antineoplastons for the manufacture of a medicament for the treatment of neurofibromatosis
KR20230022881A (ko)	2023-02-16	류마티스 관절염의 치료에서의 라벡시모드
AU2012276476B2 (en)	2017-06-29	Pharmaceutical composition for treating premature ejaculation and method for treating premature ejaculation
JP2616845B2 (ja)	1997-06-04	システノール酸又はその胆汁酸抱合体を含有する血中コレステロール低下剤
US8293755B2 (en)	2012-10-23	Treatment of statin side effects using uridine derivatives
BG63103B1 (bg)	2001-04-30	Използуване на алендронат за профилактика на остеопороза
KR20080016735A (ko)	2008-02-21	헤르페스 바이러스 유래 동통 치료제
IE903945A1 (en)	1991-05-22	Therapeutic agents
JP4766818B2 (ja)	2011-09-07	妊娠時に特異的な腰痛、股関節痛及び鼠径部痛の改善・治療剤
JP2000229853A (ja)	2000-08-22	生理痛改善用組成物
JPH0761942B2 (ja)	1995-07-05	血中尿酸濃度の低下用医薬
CN100560075C (zh)	2009-11-18	调节脂类代谢的药物
MXPA01006136A (en)	2002-03-05	Combination of cerivastatin and fibrates
JP2005247871A (ja)	2005-09-15	人工透析患者の副甲状腺機能亢進症治療組成物
SA98190566B1 (ar)	2006-05-20	إتحادات علاجية تشمل أملوديبين amlodipine وأتورفاستاتين atorvastatin